Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 1;74(4):445-452.
doi: 10.1001/jamaneurol.2016.4847.

Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion


Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion

Sara Van Mossevelde et al. JAMA Neurol. .


Importance: Patients carrying a C9orf72 repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral sclerosis have highly variable ages at onset of disease, suggesting the presence of modifying factors.

Objective: To provide clinical-based evidence for disease anticipation in families carrying a C9orf72 repeat expansion by analyzing age at onset, disease duration, and age at death in successive generations.

Design, setting, and participants: This cohort study was performed from June 16, 2000, to June 1, 2016, in 36 extended Belgian families in which a C9orf72 repeat expansion was segregating. The generational effect on age at onset, disease duration, and age at death was estimated using a mixed effects Cox proportional hazards regression model, including random-effects terms for within-family correlation and kinship. Time until disease onset or last examination, time from disease onset until death or last examination, or age at death was collected for for 244 individuals (132 proven or obligate C9orf72 carriers), of whom 147 were clinically affected (89 proven or obligate C9orf72 carriers).

Main outcomes and measures: Generational effect on age at onset, disease duration, and age at death.

Results: Among the 111 individuals with age at onset available (66 men and 45 women; mean [SD] age, 57.2 [9.1] years), the mean (SD) age at onset per generation (from earliest-born to latest-born generation) was 62.5 (8.3), 57.1 (8.2), 54.6 (10.2), and 49.3 (7.5) years. Censored regression analysis on all affected and unaffected at-risk relatives confirmed a decrease in age at onset in successive generations (P < .001). No generational effect was observed for disease duration or age at death.

Conclusions and relevance: The clinical data provide supportive evidence for the occurrence of disease anticipation in families carrying a C9orf72 repeat expansion by means of a decrease in age at onset across successive generations. This finding may help clinicians decide from which age onward it may be relevant to clinically follow presymptomatic individuals who carry a C9orf72 repeat expansion.

Similar articles

See all similar articles

Cited by 17 articles

  • Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort.
    Esselin F, Mouzat K, Polge A, Juntas-Morales R, Pageot N, De la Cruz E, Bernard E, Lagrange E, Danel V, Alphandery S, Labar L, Nogué E, Picot MC, Lumbroso S, Camu W. Esselin F, et al. Front Neurosci. 2020 Apr 28;14:316. doi: 10.3389/fnins.2020.00316. eCollection 2020. Front Neurosci. 2020. PMID: 32410933 Free PMC article.
  • Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
    Yang S, Yang H, Huang L, Chen L, Qin Z, Li S, Li XJ. Yang S, et al. Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4411-4417. doi: 10.1073/pnas.1919197117. Epub 2020 Feb 6. Proc Natl Acad Sci U S A. 2020. PMID: 32029588
  • Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers.
    Jackson JL, Finch NA, Baker MC, Kachergus JM, DeJesus-Hernandez M, Pereira K, Christopher E, Prudencio M, Heckman MG, Thompson EA, Dickson DW, Shah J, Oskarsson B, Petrucelli L, Rademakers R, van Blitterswijk M. Jackson JL, et al. Mol Neurodegener. 2020 Jan 30;15(1):7. doi: 10.1186/s13024-020-0359-8. Mol Neurodegener. 2020. PMID: 32000838 Free PMC article.
  • Recent advances in understanding frontotemporal degeneration.
    Borroni B, Benussi A. Borroni B, et al. F1000Res. 2019 Dec 13;8:F1000 Faculty Rev-2098. doi: 10.12688/f1000research.20330.1. eCollection 2019. F1000Res. 2019. PMID: 31885860 Free PMC article. Review.
  • Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.
    Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van Deerlin VM, Warren JD, Fox NC, Rossor MN, Mead S, Bocchetta M, Boeve BF, Knopman DS, Graff-Radford NR, Forsberg LK, Rademakers R, Wszolek ZK, van Swieten JC, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Snowden JS, Saxon J, Jones M, Pickering-Brown S, Le Ber I, Camuzat A, Brice A, Caroppo P, Ghidoni R, Pievani M, Benussi L, Binetti G, Dickerson BC, Lucente D, Krivensky S, Graff C, Öijerstedt L, Fallström M, Thonberg H, Ghoshal N, Morris JC, Borroni B, Benussi A, Padovani A, Galimberti D, Scarpini E, Fumagalli GG, Mackenzie IR, Hsiung GR, Sengdy P, Boxer AL, Rosen H, Taylor JB, Synofzik M, Wilke C, Sulzer P, Hodges JR, Halliday G, Kwok J, Sanchez-Valle R, Lladó A, Borrego-Ecija S, Santana I, Almeida MR, Tábuas-Pereira M, Moreno F, Barandiaran M, Indakoetxea B, Levin J, Danek A, Rowe JB, Cope TE, Otto M, Anderl-Straub S, de Mendonça A, Maruta C, Masellis M, Black SE, Couratier P, Lautrette G, Huey ED, Sorbi S, Nacmias B, Laforce R Jr, Tremblay ML, Vandenberghe R, Damme PV, Rogalski EJ, Weintraub S, Gerhard A, Onyike CU, Ducharme S, Papageorgiou SG, Ng ASL, Brodtmann A, Finger E, Guerreiro R, Bras J, Rohrer JD; FTD Prevention Initiative. Moore KM, et al. Lancet Neurol. 2020 Feb;19(2):145-156. doi: 10.1016/S1474-4422(19)30394-1. Epub 2019 Dec 3. Lancet Neurol. 2020. PMID: 31810826
See all "Cited by" articles

Publication types